- Home
- NODK vs VNDA Comparison
NODK vs VNDA Comparison
Compare NODK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- VNDA
- Stock Information
- Founded
- NODK 1946
- VNDA 2002
- Country
- NODK United States
- VNDA United States
- Employees
- NODK N/A
- VNDA N/A
- Industry
- NODK Property-Casualty Insurers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- VNDA Health Care
- Exchange
- NODK Nasdaq
- VNDA Nasdaq
- Market Cap
- NODK 327.3M
- VNDA 270.0M
- IPO Year
- NODK 2017
- VNDA 2006
- Fundamental
- Price
- NODK $14.66
- VNDA $4.38
- Analyst Decision
- NODK
- VNDA Strong Buy
- Analyst Count
- NODK 0
- VNDA 2
- Target Price
- NODK N/A
- VNDA $15.50
- AVG Volume (30 Days)
- NODK 14.9K
- VNDA 513.0K
- Earning Date
- NODK 11-07-2024
- VNDA 02-05-2025
- Dividend Yield
- NODK N/A
- VNDA N/A
- EPS Growth
- NODK N/A
- VNDA N/A
- EPS
- NODK N/A
- VNDA N/A
- Revenue
- NODK $391,655,000.00
- VNDA $190,858,000.00
- Revenue This Year
- NODK N/A
- VNDA $5.60
- Revenue Next Year
- NODK N/A
- VNDA $42.85
- P/E Ratio
- NODK N/A
- VNDA N/A
- Revenue Growth
- NODK 22.91
- VNDA N/A
- 52 Week Low
- NODK $12.71
- VNDA $3.46
- 52 Week High
- NODK $17.24
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- NODK 31.57
- VNDA 33.28
- Support Level
- NODK $14.35
- VNDA $4.77
- Resistance Level
- NODK $15.73
- VNDA $4.95
- Average True Range (ATR)
- NODK 0.35
- VNDA 0.16
- MACD
- NODK -0.12
- VNDA -0.03
- Stochastic Oscillator
- NODK 16.32
- VNDA 4.92
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.